Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2025 May;39(5):434-435.
doi: 10.1177/02698811241292944. Epub 2024 Oct 29.

Into the wild frontier: Mapping the terrain of adverse events in psychedelic-assisted therapies

Otto Simonsson  1 , Simon B Goldberg  2 , Peter S Hendricks  3
Affiliations
Comment

Into the wild frontier: Mapping the terrain of adverse events in psychedelic-assisted therapies

Otto Simonsson et al. J Psychopharmacol. 2025 May.
No abstract available

Keywords: Adverse events; commentary; psychedelics.

PubMed Disclaimer

Conflict of interest statement

Declaration of conflicting interestThe author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: OS was a co-founder of Eudelics AB and has once received a small payment from Mindfully Sweden AB for educational content. PSH was previously in paid advisory relationships with Eleusis Benefit Corporation, Reset Pharmaceuticals Inc., and Silo Pharma and is currently in paid advisory relationships with Bright Minds Biosciences Ltd. and Journey Colab Corporation. PSH is a co-founder of Equulus Therapeutics and Mycelial Health. SBG has no conflicts of interest to disclose.

Comment on

References

    1. Breeksema JJ, Kuin BW, Kamphuis J, et al. (2022) Adverse events in clinical treatments with serotonergic psychedelics and MDMA: A mixed-methods systematic review. J Psychopharmacol 36: 1100–1117. - PMC - PubMed
    1. Carhart-Harris RL, Kaelen M, Whalley MG, et al. (2015) LSD enhances suggestibility in healthy volunteers. Psychopharmacology 232: 785–794. - PubMed
    1. Colloca L, Barsky AJ. (2020) Placebo and nocebo effects. N Engl J Med 382: 554–561. - PubMed
    1. COMPASS Pathways (2018) COMPASS pathways receives FDA breakthrough therapy designation for psilocybin therapy for treatment-resistant depression. COMPASS Pathways. Available at: https://ir.compasspathways.com/News–Events-/news/news-details/2018/COMPA... (accessed 17 October 2024).
    1. Cybin (2024) Cybin receives FDA breakthrough therapy designation for its novel psychedelic molecule CYB003 and announces positive four-month durability data in major depressive disorder. Cybin. Available at: https://ir.cybin.com/investors/news/news-details/2024/Cybin-Receives-FDA... (accessed 17 October 2024).

LinkOut - more resources